- Home
- FEMY vs GSIW Comparison
FEMY vs GSIW Comparison
Compare FEMY & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- GSIW
- Stock Information
- Founded
- FEMY 2004
- GSIW 2016
- Country
- FEMY United States
- GSIW Hong Kong
- Employees
- FEMY N/A
- GSIW N/A
- Industry
- FEMY Medical/Dental Instruments
- GSIW
- Sector
- FEMY Health Care
- GSIW
- Exchange
- FEMY Nasdaq
- GSIW Nasdaq
- Market Cap
- FEMY 29.9M
- GSIW 27.2M
- IPO Year
- FEMY 2021
- GSIW 2023
- Fundamental
- Price
- FEMY $0.94
- GSIW $1.75
- Analyst Decision
- FEMY Strong Buy
- GSIW
- Analyst Count
- FEMY 3
- GSIW 0
- Target Price
- FEMY $8.67
- GSIW N/A
- AVG Volume (30 Days)
- FEMY 259.3K
- GSIW 2.6M
- Earning Date
- FEMY 08-07-2025
- GSIW 01-01-0001
- Dividend Yield
- FEMY N/A
- GSIW N/A
- EPS Growth
- FEMY N/A
- GSIW N/A
- EPS
- FEMY N/A
- GSIW N/A
- Revenue
- FEMY $1,699,232.00
- GSIW $1,313,795.00
- Revenue This Year
- FEMY $283.83
- GSIW N/A
- Revenue Next Year
- FEMY $161.03
- GSIW N/A
- P/E Ratio
- FEMY N/A
- GSIW N/A
- Revenue Growth
- FEMY 61.97
- GSIW N/A
- 52 Week Low
- FEMY $0.69
- GSIW $0.35
- 52 Week High
- FEMY $1.80
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- FEMY 50.13
- GSIW 72.13
- Support Level
- FEMY $0.91
- GSIW $1.26
- Resistance Level
- FEMY $0.99
- GSIW $1.66
- Average True Range (ATR)
- FEMY 0.05
- GSIW 0.14
- MACD
- FEMY 0.00
- GSIW -0.02
- Stochastic Oscillator
- FEMY 28.50
- GSIW 92.25
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.